For over 20 years, Asymchem has been positioned and structured to act as a true partner for pharmaceutical and biotech companies worldwide by offering integrated solutions across all stages of drug development and into commercialization.
As a CDMO with 8 state-of-the-art manufacturing sites, Asymchem’s breadth of capabilities spans conventional batch manufacturing, and we are a world leader in green chemistry. Our scientists excel in the creation and manufacture of enzymes for use in bio-catalysis, and the development of practical continuous flow technologies for commercialization. In addition to strong supply chain relationships, Asymchem maintains a dedicated facility for the in-house production of raw materials and regulatory starting materials to better control quality, costs and lead times.
Asymchem has partnered with more than 400 clients across the globe, and is currently involved in more than 600 ongoing clinical projects and 30 commercial projects. We have a consistently demonstrated ability to meet project deadlines and achieve commercialization success, while exemplifying the long-term financial stability critical to project continuity and achievement. Our work has frequently won us “most valuable partner” and “strategic partner” recognition from major pharma and leading biotech companies.
Asymchem's presents their High Potency and Oral Solid Dose capabilities and capacity in the June 2022 edition of the Outsourced Pharma Capacity Update.
We're a CDMO that researches the possibilities, develops new technologies, and applies new processes in a continual drive toward optimization.